ArticleGenome medicine2026
Spatial multi-omics characterization of neuroblastoma reveals ferroptosis-associated metabolic features in high-risk tumors.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Emerging Role of Ferroptosis in Pediatric Cancer Biology and Therapy.International journal of molecular sciences · 2026Review
- Review
- Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy.Frontiers in oncology · 2026Review
- Manufacturing cost analysis and exploratory economic evaluation of natural killer cell immunotherapy for paediatric solid tumors.Clinical & translational immunology · 2026Article
- The B7-H3/CD3 immune phenotype identifies prognostic subgroups in neuroblastoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroblastoma is a tumor of the sympathetic nervous system and is the most common extracranial solid malignancy in children. It displays striking clinical heterogeneity, ranging from spontaneous regression to a more aggressive, treatment resistant disease. While previous studies have highlighted the importance of the tumor microenvironment (TME) in shaping disease behavior, how spatial organization and metabolic pathways contribute to high-risk neuroblastoma remains poorly understood.
methodsHere, we performed spatial transcriptomics profiling using the GeoMx Digital Spatial Profiler (DSP) Whole Transcriptome Atlas (WTA) and a spatial proteomics profile using the Akoya PhenoCycler-Fusion on a cohort of human pediatric neuroblastoma samples to characterize tumor and TME regions.
resultsBy using the GeoMx WTA panel, high-risk neuroblastoma tumor regions were found to exhibit upregulation of metabolic pathways associated with ferroptosis, including fatty acid metabolism and reactive oxygen species (ROS) signaling. However, these tumors also showed increased glutathione metabolism pathway and elevated GPX4 expression, consistent with a potential compensatory response that may limit ferroptosis-associated cell death. Further in vitro experiments showed that inhibition of GPX4 increased lipid peroxidation and reduced tumor cell viability, consistent with ferroptosis-related processes. Interestingly, spatial proteomic analysis revealed distinct spatial niches in high-risk neuroblastoma, including stroma-secluded immune cells and macrophage enriched areas, both of which were correlated with poor patient survival.
conclusionsOur integrative spatial multi-omics analysis suggests that high-risk neuroblastoma tumors display ferroptosis-associated metabolic features, with GPX4 inhibition inducing neuroblastoma tumor cell death. We also identify macrophage-tumor interactions that may be linked to ferroptosis sensitivity. Collectively, our study highlights ferroptosis-associated pathways as potential therapeutic avenues in neuroblastoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.